

vs : 36.44 ± 13.94 , 46.86 ± 8.15 , $t = -2.48$, $p < 0.05$) (vs : 8.61 ± 6.36 , 13.64 ± 7.08 , $t = -2.11$, $p < 0.05$) 가 , ($\beta = 0.22$, $SE = 0.11$, $OR = 1.25$, $p < 0.05$) .⁴³⁾

비전형 항정신병 약물은 자살을 감소시키는데 효과적일까?

clozapine, risperidone, olanzapine, quetiapine, ziprasidone, iloperidone

가
가

(29,51 - 55)

가

항정신병 약물, 항우울제, 기분 안정제와 자살

Clozapine, olanzapine (mood stabilizing effects)

가 , , clozapine

가

가

가 가 ,

44)

clozapine

가

45,46)

Clozapine

가

clozapine 가 가
clozapine
가,
가

(noncompliance),
()

(mood sta-

clozapine

bilizer), (anticonvulsants)

가 ,

47 - 50)

56 - 59)

clozapine

(mood

stabilizing)

가

60 - 62)

clozapine , 가 clozapine olanzapine .

clozapine olanzapine

clozapine (hazard ratio, 0.76 : 95% confidence interval, 0.58 - 0.97 : P=.03). clozapine

가 . clozapine

가 ⁶³⁾ ,

Clozapine olanzapine

Meltzer Okayli²⁶⁾가 1986 1993

183

clozapine 5.6%, olanzapine 8.5%

10%

Meltzer ⁶⁵⁾ cloza-

pine

가 , clozapine

clozapine

0.18% ,

10%

1~2%, 0.4~0.8%

Meltzer ²⁶⁾ clozapine

Olanzapine

US Clozaril National Registry Olanzapine

clozapine Glazzer⁶⁹⁾ 가 ,

가 ^{64 - 67)} .

clozapine 가 ²⁹⁾ , Clo-

Glazzer⁶⁹⁾ 1 olanzapine

haloperidol

Beasley ⁶⁴⁾

clozapine - olanzapine haloperidol,

가 ,

clozapine olanzapine, haloperidol

Davis ⁵²⁾ olanzapine, haloperidol

, olanzapine

olanzapine

Meltzer ⁶⁸⁾ clozapine 가

, olanzapine

International Suicide Prevention Trial(Inter-

SePT) clozapine

가 .

결론

(80%), (25%) 10%
가 ,

가
가 ,
가
가
가

중심 단어 :

REFERENCES

- Allebeck P. Schizophrenia: a life-shortening disease. *Schizophr Bull* 1989;15:81-89.
- Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. *Schizophr Bull* 1990;16:571-589.
- Heila H, Isometsa ET, Henriksson MM, Heikkinen ME, Marttunen MJ, Lonnqvist JK. Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. *Am J Psychiatry* 1997;154:1235-1242.
- Miles CP. Conditions predisposing to suicide: a review. *J Nerv Ment Dis* 1977;164:231-246.
- Cohen LJ, Test MA, Brown RL. Suicide and schizophrenia: data from a prospective community treatment study. *Am J Psychiatry* 1990;147:602-607.
- Harris EC, Barraclough E. Excess mortality of mental disorder. *Br J Psychiatry* 1998;173:11-53.
- Lindelius R, Kay DW. Some changes in the pattern of mortality in schizophrenia, in Sweden. *Acta Psychiatr Scand* 1973;49:315-323.
- Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. *Br J Psychiatry* 1993;163:183-189.
- Fenton WS. Depression, suicide, and suicide prevention in schizophrenia. *Suicide Life Threat Behav* 2000;30:34-49.
- Drake RE, Cotton PG. Depression, hopelessness and suicide in chronic schizophrenia. *Br J Psychiatry* 1986;148:554-559.
- De Hert M, McKenzie K, Peuskens J. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. *Schizophr Res* 2001;47:127-134.
- Harkavy-Friedman JM, Restifo K, Malaspina D, Kaufmann CA, Amador XF, Yale SA, et al. Suicidal behavior in schizophrenia: characteristics of individuals who had and had not attempted suicide. *Am J Psychiatry* 1999;156:1276-1278.
- Heila H, Heikkinen ME, Isometsa ET, Henriksson MM, Marttunen MJ, Lonnqvist JK. Life events and completed suicide in schizophrenia: a comparison of suicide victims with and without schizophrenia. *Schizophr Bull* 1999;25:519-531.
- Kim CH, Jayatilake K, Alphas L, Green AI, Anand R, Meltzer HY. Risk factors in patients with schizophrenia and schizoaffective disorders who are at high risk for suicide. *대한정신분열병학회 춘계 학술대회*. 2003년 5월 9일, 서울: 대한정신분열병학회;2003. p.119.
- Kaplan KJ, Harrow M. Positive and negative symptoms as risk factors for later suicidal activity in schizophrenics vs depressives. *Suicide Life Threat Behav* 1996;26:105-121.
- Young AS, Nuechterlein KH, Mintz J, Ventura J, Gitlin M, Liberman RP. Suicidal ideation and suicide attempts in recent-onset schizophrenia. *Schizophr Bull* 1998;24:629-634.
- Zubin J. Observation on nosological issue in the classification of suicidal behavior. In: Beck AT, Resnik HLP, Lettieri DJ, editors. *The prediction of suicide*. Philadelphia: Charles Press, publishers;1974. p.3-25.
- Lindenmayer JP, Czobor P, Alphas L, Nathan A, Anand R, Islam Z, et al. The InterSePT scale for suicidal thinking reliability and validity. *Schizophrenia Research* In Press;2002.
- Roy-Byrne PP, Post RM, Hambrick DD, Leverich GS, Rosoff AS. Suicide and course of illness in major depressive disorder. *J Affect Dis* 1988;15:1-8.
- Beck AT, Steer RA, Kovacs M, Garrison B. Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. *Am J Psychiatry* 1985;142:559-563.
- Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. *Arch Gen Psychiatry* 1999;56:617-626.
- Shaffer JW, Perlin S, Schmidt CW Jr, Stephens JH. The prediction of suicide in schizophrenia. *J Nerv Ment Dis* 1974;159:349-355.
- Krausz M, Muller-Thomsen T, Haasen C. Suicide among schizophrenic adolescents in the long-term course of illness. *Psychopathology* 1995;28:95-103.
- Breier A, Astrachan BM. Characterization of schizophrenic patients who commit suicide. *Am J Psychiatry* 1984;141:206-209.
- Gupta S, Black DW, Arndt S, Hubbard WC, Andreasen NC. Factors associated with suicide attempts among patients with schizophrenia. *Psychiatr Serv* 1998;49:1353-1355.
- Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. *Am J Psychiatry* 1995;152:183-190.
- Kim CH, Jayatilake K, Meltzer HY. Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior. *Schizophr Res* 2003;60:71-80.
- 남윤영, 김찬형, 서호석, 신의진, 손영호, 이홍식. 정신분열병 환자의 우울증, 절망감, 충동성 및 병식이 자살행동에 미치는 영향. *대한정신분열병학회 춘계 학술대회*. 2003년 5월 9일, 서울: 대한정신분열병학회;2003. p.118-119.
- Meltzer HY. Treatment of suicidality in schizophrenia. *Ann NY Acad Sci* 2001 Apr;932:44-58.
- Amador XF, Friedman JH, Kasapis C, Yale SA, Flaum M, Gorman JM. Suicidal behavior in schizophrenia and its relationship to awareness of illness. *Am J Psychiatry* 1996;153:1185-1188.
- Lysaker PH, Bell MD, Bryson G, Kaplan E. Neurocognitive function and insight in schizophrenia: support for an association with impairments in executive function but not with impairments in global function. *Acta Psychiatr Scand* 1998;97:297-301.
- Young DA, Davila R, Scher H. Unawareness of illness and neuropsychological performance in chronic schizophrenia. *Schizophr Res* 1993;10:117-124.
- Kemp R, David A. Psychological predictors of insight and compliance in psychotic patients. *Br J Psychiatry* 1996;169:444-450.
- Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. *Am J Psychiatry* 2001;158:1783-1793.
- Brodsky BS, Oquendo M, Ellis SP, Haas GL, Malone KM, Mann JJ. The relationship of childhood abuse to impulsivity and suicidal behavior

- in adults with major depression. *Am J Psychiatry* 2001;158:1871-1877.
- 36) Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. *Am J Psychiatry* 1999; 156:181-189.
 - 37) Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. *J Clin Psychiatry* 2000;61 (Suppl 9):97-104.
 - 38) Baldessarini RJ, Tondo L, Hennen J. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. *Ann NY Acad Sci* 2001;932:24-38.
 - 39) Koller G, Preuss UW, Bottlender M, Wenzel K, Soyka M. Impulsivity and aggression as predictors of suicide attempts in alcoholics. *Eur Arch Psychiatry Clin Neurosci* 2002;252:155-160.
 - 40) Herpertz S, Sass H, Favazza A. Impulsivity in self-mutilative behavior: psychometric and biological findings. *J Psychiatr Res* 1997;31:451-465.
 - 41) Dervaux A, Bayle FJ, Laqueille X, Bourdel MC, Le Borgne MH, Olie JP, et al. Is substance abuse in schizophrenia related to impulsivity, sensation seeking, or anhedonia? *Am J Psychiatry* 2001;158: 492-494.
 - 42) Gut-Fayand A, Dervaux A, Olie JP, L  o H, Poirier MF, Krebs MO. Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. *Psychiatry research* 2001;102:65-72.
 - 43) 김찬형, 남윤영, 서호석, 이홍식. 정신분열병 환자의 우울증, 절망감, 충동성, 병식이 자살 시도의 폭력성에 미치는 영향. 대한정신분열병학회 춘계 학술대회. 2003년 5월 9일, 서울: 대한정신분열병학회;2003. p.117-118.
 - 44) Palmer DD, Henter ID, Wyatt RJ. Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? *J Clin Psychiatry* 1999;60 (Suppl 2) :100-103.
 - 45) Ciompi L. 1976. Late suicide in former mental patients. *Psychiatr Clin (Basel)* 1976;9:59-63.
 - 46) Winokur G, Tsuang M. The Iowa 500: suicide in mania, depression, and schizophrenia. *Am J Psychiatry* 1975;132:650-651.
 - 47) Drake RE, Ehrlich J. Suicide attempts associated with akathisia. *Am J Psychiatry* 1985;142:499-501.
 - 48) Shear MK, Frances A, Weiden P. Suicide associated with akathisia and depot fluphenazine treatment. *J Clin Psychopharmacol* 1983;3:235-236.
 - 49) Gaertner I, Gilot C, Heidrich P, Gaertner HJ. A case control study on psychopharmacotherapy before suicide committed by 61 psychiatric inpatients. *Pharmacopsychiatry* 2002;35:37-43.
 - 50) Azorin JM. Long-term treatment of mood disorders in schizophrenia. *Acta Psychiatr Scand* 1995;388 (Suppl) :20-23.
 - 51) Keck PE Jr, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. *J Clin Psychiatry* 2000;61 (Suppl3) :4-9.
 - 52) Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. *J Clin Psychiatry* 2001;62 (10) : 757-771.
 - 53) Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. *J Clin Psychopharmacol* 1997;17:407-418.
 - 54) Buckley P, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. *Am J Psychiatry* 1994;151:385-389.
 - 55) Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. *Pharmacopsychiatry* 1993;26:121-124.
 - 56) Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. *Br J Psychiatry* 1991; 158:503-510.
 - 57) Meltzer HY. Treatment-resistant schizophrenia: the role of clozapine. *Curr Med Res Opin* 1997;14:1-20.
 - 58) Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. *Arch Gen Psychiatry* 1988;45:789-796.
 - 59) Banov MD, Zarate CA Jr, Tohen M, Scialappa D, Wines JD Jr, Kolbrenner M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. *J Clin Psychiatry* 1994;55:295-300.
 - 60) Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, et al. Clozapine in the treatment of refractory psychotic mania. *Am J Psychiatry* 2000;157:982-986.
 - 61) McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. *J Clin Psychiatry* 1991;52: 411-414.
 - 62) Naber D, Hippus H. The European experience with use of clozapine. *Hosp Community Psychiatry* 1990;41:886-890.
 - 63) Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. *Hosp Community Psychiatry* 1990;41:892-897.
 - 64) Beasley CM, Sayler ME, Kiesler GM, J Potvin H, Sanger TM, Tollefson GD. The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia. *Schizophr Res* 1998;29:28.
 - 65) Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. *Psychiatr Serv* 1998;49:1029-1033.
 - 66) Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. *Epidemiology*. 1997;8:671-677.
 - 67) Spivak B, Mester R, Wittenberg N, Maman Z, Weizman A. Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. *Clin Neuropharmacol* 1997;20:442-446.
 - 68) Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). *Arch Gen Psychiatry* 2003; 60:82-91.
 - 69) Glazer W. Formulary decisions and health economics. *J Clin Psychiatry* 1998;59 (suppl 19) :23-29.